OBJECTIVES: We conducted a systematic review to assess the design and 'failure definition' in studies of biologic discontinuation in rheumatoid arthritis (RA). METHODS: We found 403 studies on PubMed, and included nine published papers and five abstracts from scientific meetings. We used a structured extraction form to collect information regarding study design and outcome (failure) definition. RESULTS: Three types of studies were found: randomised controlled trials, long-term extension studies of clinical trials and prospective discontinuation studies. The largest study had 196 subjects in the discontinuation arm. Most studies allowed concomitant use of non-biologic drugs at biologic discontinuation. Heterogeneity was also found in the failure definition. Although all studies used measures of disease activity, the threshold for failure and the time point of assessment differed among studies. Few studies incorporated changing use of non-biologic drugs or glucocorticoids into the failure definition. CONCLUSIONS: Although many studies have examined the outcome of biologic discontinuation, they have all been relatively small. Typical practice studies from registries may add important information but will likely need to rely on a broader failure definition.
OBJECTIVES: We conducted a systematic review to assess the design and 'failure definition' in studies of biologic discontinuation in rheumatoid arthritis (RA). METHODS: We found 403 studies on PubMed, and included nine published papers and five abstracts from scientific meetings. We used a structured extraction form to collect information regarding study design and outcome (failure) definition. RESULTS: Three types of studies were found: randomised controlled trials, long-term extension studies of clinical trials and prospective discontinuation studies. The largest study had 196 subjects in the discontinuation arm. Most studies allowed concomitant use of non-biologic drugs at biologic discontinuation. Heterogeneity was also found in the failure definition. Although all studies used measures of disease activity, the threshold for failure and the time point of assessment differed among studies. Few studies incorporated changing use of non-biologic drugs or glucocorticoids into the failure definition. CONCLUSIONS: Although many studies have examined the outcome of biologic discontinuation, they have all been relatively small. Typical practice studies from registries may add important information but will likely need to rely on a broader failure definition.
Authors: M van den Broek; N B Klarenbeek; L Dirven; D van Schaardenburg; H M J Hulsmans; P J S M Kerstens; T W J Huizinga; B A C Dijkmans; C F Allaart Journal: Ann Rheum Dis Date: 2011-04-24 Impact factor: 19.103
Authors: Jacqueline Detert; Hans Bastian; Joachim Listing; Anja Weiß; Siegfried Wassenberg; Anke Liebhaber; Karin Rockwitz; Rieke Alten; Klaus Krüger; Rolf Rau; Christina Simon; Eva Gremmelsbacher; Tanja Braun; Bettina Marsmann; Vera Höhne-Zimmer; Karl Egerer; Frank Buttgereit; Gerd-R Burmester Journal: Ann Rheum Dis Date: 2012-06-27 Impact factor: 19.103
Authors: Aatke van der Maas; Wietske Kievit; Bart J F van den Bemt; Frank H J van den Hoogen; Piet L van Riel; Alfons A den Broeder Journal: Ann Rheum Dis Date: 2012-04-13 Impact factor: 19.103
Authors: Karin Bruynesteyn; Désirée van der Heijde; Maarten Boers; Ariane Saudan; Paul Peloso; Harold Paulus; Harry Houben; Bridget Griffiths; John Edmonds; Barry Bresnihan; Annelies Boonen; Sjef van der Linden Journal: Arthritis Rheum Date: 2002-04
Authors: Mark A Quinn; Philip G Conaghan; Philip J O'Connor; Zunaid Karim; Adam Greenstein; Andrew Brown; Clare Brown; Alexander Fraser; Stephen Jarret; Paul Emery Journal: Arthritis Rheum Date: 2005-01
Authors: Josef S Smolen; Peter Nash; Patrick Durez; Stephen Hall; Elena Ilivanova; Fedra Irazoque-Palazuelos; Pedro Miranda; Min-Chan Park; Karel Pavelka; Ronald Pedersen; Annette Szumski; Constance Hammond; Andrew S Koenig; Bonnie Vlahos Journal: Lancet Date: 2013-01-17 Impact factor: 79.321
Authors: Susan J Bartlett; Sarah Hewlett; Clifton O Bingham; Thasia G Woodworth; Rieke Alten; Christoph Pohl; Ernest H Choy; Tessa Sanderson; Annelies Boonen; Vivian Bykerk; Amye L Leong; Vibeke Strand; Daniel E Furst; Robin Christensen Journal: Ann Rheum Dis Date: 2012-07-06 Impact factor: 19.103
Authors: Seemal R Desai; Ilona J Frieden; Joel M Gelfand; Whitney High; Arthur Kavanaugh; Ashfaq A Marghoob; David M Ozog; Ted Rosen; Linda Stein Gold; Bruce Strober; Neil Swanson; George Martin Journal: J Clin Aesthet Dermatol Date: 2015-09
Authors: Maria D Mjaavatten; Helga Radner; Kazuki Yoshida; Nancy A Shadick; Michelle L Frits; Christine K Iannaccone; Tore K Kvien; Michael E Weinblatt; Daniel H Solomon Journal: Semin Arthritis Rheum Date: 2014-08-27 Impact factor: 5.532
Authors: Susan J Bartlett; Skye P Barbic; Vivian P Bykerk; Ernest H Choy; Rieke Alten; Robin Christensen; Alfons den Broeder; Bruno Fautrel; Daniel E Furst; Francis Guillemin; Sarah Hewlett; Amye L Leong; Anne Lyddiatt; Lyn March; Pamela Montie; Christoph Pohl; Marieke Scholte Voshaar; Thasia G Woodworth; Clifton O Bingham Journal: J Rheumatol Date: 2017-08-15 Impact factor: 4.666
Authors: Lise M Verhoef; Bart Jf van den Bemt; Aatke van der Maas; Johanna E Vriezekolk; Marlies E Hulscher; Frank Hj van den Hoogen; Wilco Ch Jacobs; Noortje van Herwaarden; Alfons A den Broeder Journal: Cochrane Database Syst Rev Date: 2019-05-24